ArriVent BioPharma and Allist Pharmaceuticals unveiled groundbreaking data from their global Phase Ib proof-of-concept randomized study (FURTHER) at the IASCLC 2024 WCLC.

Terns Pharmaceuticals Reports Successful Phase 1 Results for TERN-601 Daily Oral GLP-1R Agonist in Obesity Treatment.

The Synapse database immediately launched a search portal for ESMO clinical results data, facilitating user access.

The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.

Sep 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).

Competing in the $40 Billion Alopecia Areata Market: Hengrui's JAK1 Inhibitor Ivarmacitinib Receives Approval for New Indication Application.

Ventyx Biosciences announced that the initial patient has been administered a dose in a Phase 2a study of VTX3232 for individuals with early-stage Parkinson’s disease.

Cytonics Completes Phase 1 Enrollment for Study on CYT-108, a New Protease Inhibitor, in Knee Osteoarthritis Patients.

Sep 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Huonslab Reveals Favorable In Vivo PK Study Outcomes for Trastuzumab/HyDIFFUZETM vs. Commercial rHuPH20 and Trastuzumab Co-formulation.

NextPoint Therapeutics Reveals NPX372, a Novel Drug Targeting B7-H7 in Solid Tumors, as New T Cell Engager.